Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET S891A |
| Therapy | Vandetanib |
| Indication/Tumor Type | medullary thyroid carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET S891A | medullary thyroid carcinoma | predicted - sensitive | Vandetanib | Case Reports/Case Series | Actionable | In a clinical case study, neoadjuvant Caprelsa (vandetanib) treatment resulted in a 65% decrease in the thyroid mass and cervical lymph nodes allowing for surgical resection in a pediatric patient with medullary thyroid carcinoma harboring RET S891A (PMID: 38207224). | 38207224 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38207224) | Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma. | Full reference... |